← Leaderboards
Mark W. Lingen
Loyola University Chicago
$8,856,572
Attributed
$9,821,581
Total exposure
11
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,000,761 · 12
By mechanism
R01$5,514,796 · 3
P30$2,306,819 · 2
RC2$770,000 · 1
K02$600,004 · 1
P20$450,782 · 1
S10$358,360 · 4
Top collaborators
- Nishant Agrawal5 shared
Most similar at Loyola University Chicago
Same institution · by research overlap
- M. Rita Young$5,685,619
- Andrew Volk$2,839,488
- Domenick Edward Kennedy$152,699
Others in their field
Top investigators on “Human Tissue”
- David Heimbrook · Leidos Biomedical Research, Inc.$294,443,261
- Lawrence Corey · Fred Hutchinson Cancer Center$212,638,156
- Larry Arthur$131,303,476
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$114,079,276
- Peter Gordon Gillespie · Oregon Health And Science University$104,808,120
- Kevin Urdahl · Seattle Children'S Hospital$85,664,942
Research focus
Human TissueMalignant NeoplasmsHistologicTissuesMolecularSalivaCollectionEvaluationDetectionSamplingOnline SystemsFutureResearch PersonnelPathologistChemopreventionProgramsTissue MicroarrayDiagnosticConsentUniversitiesChicagoServicesLesionAngiogenesis Inhibitors
Grant awards (42)
Human Tissue Resource Center$213,096
P30 · FY2025 · CA · contact PI
Somatic Mutations in Tissue and Saliva as Prognostic and Screening Biomarkers for Oral Premalignancy$378,308
R01 · FY2024 · DE
Human Tissue Resource Center$293,945
P30 · FY2024 · CA · contact PI
Somatic Mutations in Tissue and Saliva as Prognostic and Screening Biomarkers for Oral Premalignancy$386,028
R01 · FY2023 · DE
Somatic Mutations in Tissue and Saliva as Prognostic and Screening Biomarkers for Oral Premalignancy$396,183
R01 · FY2022 · DE
Human Tissue Resource Center$353,672
P30 · FY2022 · CA · contact PI
Somatic Mutations in Tissue and Saliva as Prognostic and Screening Biomarkers for Oral Premalignancy$384,750
R01 · FY2021 · DE
Human Tissue Resource Center$355,733
P30 · FY2021 · CA · contact PI
Somatic Mutations in Tissue and Saliva as Prognostic and Screening Biomarkers for Oral Premalignancy$384,750
R01 · FY2020 · DE
Human Tissue Resource Center$355,733
P30 · FY2020 · CA · contact PI
Biospecimen and Pathology Core$151,778
P20 · FY2020 · CA · contact PI
Human Tissue Resource Center$4,735
P30 · FY2020 · CA · contact PI
Human Tissue Resource Center$355,733
P30 · FY2019 · CA · contact PI
Biospecimen and Pathology Core$147,226
P20 · FY2019 · CA · contact PI
Human Tissue Resource Center$368,823
P30 · FY2018 · CA · contact PI
Biospecimen and Pathology Core$151,778
P20 · FY2018 · CA · contact PI
Human Tissue Resource Center$2,728
P30 · FY2018 · CA · contact PI
Human Tissue Resource Center$2,621
P30 · FY2018 · CA · contact PI
Efficacy of Oral Cancer Screening Adjunctive Techniques$770,000
RC2 · FY2009 · DE · contact PI
Oral Cancer, Chemoprevention, and Anti-Angiogenesis$337,825
R01 · FY2009 · DE · contact PI
Oral Cancer, Chemoprevention, and Anti-Angiogenesis$350,133
R01 · FY2008 · DE · contact PI
Molecular Profiling of Premalignant Oral Lesions$311,993
R01 · FY2008 · DE · contact PI
Oral Cancer, Chemoprevention, and Anti-Angiogenesis$341,582
R01 · FY2007 · DE · contact PI
Molecular Profiling of Premalignant Oral Lesions$316,626
R01 · FY2007 · DE · contact PI
Oral Cancer, Chemoprevention, and Anti-Angiogenesis$351,784
R01 · FY2006 · DE · contact PI
Molecular Profiling of Premalignant Oral Lesions$327,954
R01 · FY2006 · DE · contact PI
Oral Cancer, Chemoprevention, and Anti-Angiogenesis$373,375
R01 · FY2005 · DE
Molecular Profiling of Premalignant Oral Lesions$347,405
R01 · FY2005 · DE
MOLECULAR DETERMINANTS OF ANGIOGENSIS IN ORAL CANCER$129,481
K02 · FY2005 · DE
Automated Tissue Arrayer$179,180
S10 · FY2004 · RR
MOLECULAR DETERMINANTS OF ANGIOGENSIS IN ORAL CANCER$129,481
K02 · FY2004 · DE
AUTO TISSUE ARRAYER: CANCER: PROSTATE, ORAL, LUNG, LEUKEMIA, COLON, BREAST$59,728
S10 · FY2004 · RR
AUTO TISSUE ARRAYER: CROHN'S DISEASE, CELIAC DISEASE, INFLAMMATORY BOWEL DISEASE$59,726
S10 · FY2004 · RR
AUTO TISSUE ARRAYER: ASTHMA$59,726
S10 · FY2004 · RR
MOLECULAR DETERMINANTS OF ANGIOGENSIS IN ORAL CANCER$129,481
K02 · FY2003 · DE
ORAL CANCER, RETINOIDS, AND ANTIANGIOGENESIS$110,588
R01 · FY2002 · DE
MOLECULAR DETERMINANTS OF ANGIOGENSIS IN ORAL CANCER$89,291
K02 · FY2002 · DE
ORAL CANCER, RETINOIDS, AND ANTIANGIOGENESIS$70,226
R01 · FY2002 · DE
MOLECULAR DETERMINANTS OF ANGIOGENSIS IN ORAL CANCER$40,190
K02 · FY2002 · DE
ORAL CANCER, RETINOIDS, AND ANTIANGIOGENESIS$175,195
R01 · FY2001 · DE
MOLECULAR DETERMINANTS OF ANGIOGENSIS IN ORAL CANCER$82,080
K02 · FY2001 · DE
ORAL CANCER, RETINOIDS, AND ANTIANGIOGENESIS$170,091
R01 · FY2000 · DE